Efficacy and Safety of 500mg of Fulvestrant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.

Trial Locations (5)

02114

Massachusetts General Hosptial, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

01854

Lowell General Hospital, Lowell

02190

South Shore Hospital, South Weymouth

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Lowell General Hospital

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

University of Maryland Greenebaum Cancer Center

OTHER

collaborator

South Shore Hospital

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER